154 related articles for article (PubMed ID: 25413577)
21. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.
Liefvendahl E; Arnqvist HJ
Horm Metab Res; 2008 Jun; 40(6):369-74. PubMed ID: 18393172
[TBL] [Abstract][Full Text] [Related]
22. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.
Hansen BF; Danielsen GM; Drejer K; Sørensen AR; Wiberg FC; Klein HH; Lundemose AG
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):271-9. PubMed ID: 8670118
[TBL] [Abstract][Full Text] [Related]
23. Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells.
Pepe MG; Ginzton NH; Lee PD; Hintz RL; Greenberg PL
J Cell Physiol; 1987 Nov; 133(2):219-27. PubMed ID: 2960684
[TBL] [Abstract][Full Text] [Related]
24. Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.
Brierley GV; Macaulay SL; Forbes BE; Wallace JC; Cosgrove LJ; Macaulay VM
Endocrinology; 2010 Apr; 151(4):1418-27. PubMed ID: 20179263
[TBL] [Abstract][Full Text] [Related]
25. Effects of insulin, insulin-like growth factor-I and -II on proliferation and intracellular signaling in endometrial carcinoma cells with different expression levels of insulin receptor isoform A.
Wang CF; Zhang G; Zhao LJ; Li XP; Qi WJ; Wang JL; Wei LH
Chin Med J (Engl); 2013; 126(8):1560-6. PubMed ID: 23595395
[TBL] [Abstract][Full Text] [Related]
26. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
27. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
28. Mitogenic and metabolic effects of type I IGF receptor overexpression in insulin receptor-deficient hepatocytes.
Kim JJ; Park BC; Kido Y; Accili D
Endocrinology; 2001 Aug; 142(8):3354-60. PubMed ID: 11459778
[TBL] [Abstract][Full Text] [Related]
29. IGF-I/insulin hybrid receptors in human endothelial cells.
Nitert MD; Chisalita SI; Olsson K; Bornfeldt KE; Arnqvist HJ
Mol Cell Endocrinol; 2005 Jan; 229(1-2):31-7. PubMed ID: 15607526
[TBL] [Abstract][Full Text] [Related]
30. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.
Sciacca L; Mineo R; Pandini G; Murabito A; Vigneri R; Belfiore A
Oncogene; 2002 Nov; 21(54):8240-50. PubMed ID: 12447687
[TBL] [Abstract][Full Text] [Related]
31. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
32. Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression.
Sciacca L; Cassarino MF; Genua M; Vigneri P; Giovanna Pennisi M; Malandrino P; Squatrito S; Pezzino V; Vigneri R
J Cell Physiol; 2014 Nov; 229(11):1817-21. PubMed ID: 24683100
[TBL] [Abstract][Full Text] [Related]
33. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells.
Chisalita SI; Arnqvist HJ
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E896-901. PubMed ID: 14722023
[TBL] [Abstract][Full Text] [Related]
36. Human microvascular endothelial cells are sensitive to IGF-I but resistant to insulin at the receptor level.
Johansson GS; Chisalita SI; Arnqvist HJ
Mol Cell Endocrinol; 2008 Dec; 296(1-2):58-63. PubMed ID: 18708119
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals.
Esposito DL; Blakesley VA; Koval AP; Scrimgeour AG; LeRoith D
Endocrinology; 1997 Jul; 138(7):2979-88. PubMed ID: 9202243
[TBL] [Abstract][Full Text] [Related]
38. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A.
Sacco A; Morcavallo A; Pandini G; Vigneri R; Belfiore A
Endocrinology; 2009 Aug; 150(8):3594-602. PubMed ID: 19443570
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects.
Federici M; Zucaro L; Porzio O; Massoud R; Borboni P; Lauro D; Sesti G
J Clin Invest; 1996 Dec; 98(12):2887-93. PubMed ID: 8981937
[TBL] [Abstract][Full Text] [Related]
40. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
